Cambridge Cancer Genomics

Member Type: Emerging Biotech/Pharmaceutical Companies

Cambridge Cancer Genomics is an 18-month-old start-up backed by venture capital, with an award-winning history and international recognition from prestigious programs including Y combinator. They are transforming the way cancer patients are treated, through next generation liquid biopsies and smart genomics.

Join Today

PMC members shape and advance the future of personalized medicine.
Join Today

Download a Member List

Member List (PDF)